Antenatal magnesium sulphate exposure is associated with prolonged parathyroid hormone suppression in preterm neonates.
The effects of maternal magnesium sulphate treatment on neonatal mineral status and parathyroid hormone secretory response were studied in 8 exposed and 27 control preterm infants during the first 2 wk of life. Antenatal magnesium sulphate resulted in hypermagnesaemia during the first 3-7 d of life without affecting other serum mineral concentrations.


CONCLUSIONS
Early hypermagnesaemia was associated with hypercalciuria during the first 3 d and parathyroid hormone suppression up to the age of 2 wk in the exposed infants.
Rantonen
T
T
Cardiorespiratory Research Unit, University of Turku, Finland. tiiran@utu.fi
Kääpä
P
P
Jalonen
J
J
Ekblad
U
U
Peltola
O
O
Välimäki
I
I
Kero
P
P
D002118:Calcium / Q000097:blood / Q000652:urine; D005260:Female; D005312:Fetal Blood / Q000737:chemistry; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D008274:Magnesium / Q000097:blood / Q000652:urine; D008278:Magnesium Sulfate / Q000009:adverse effects* / Q000627:therapeutic use; D010281:Parathyroid Hormone / Q000097:blood / Q000172:deficiency*; D010758:Phosphorus / Q000097:blood / Q000652:urine; D011225:Pre-Eclampsia / Q000188:drug therapy; D011247:Pregnancy; D015149:Tocolytic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D014131:Trace Elements / Q000097:blood* / Q000652:urine
D010281:Parathyroid Hormone; D015149:Tocolytic Agents; D014131:Trace Elements; D010758:Phosphorus; D008278:Magnesium Sulfate; D008274:Magnesium; D002118:Calcium